{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T03:17:06Z","timestamp":1791515826967,"version":"4.3.4"},"reference-count":182,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.bmc.2026.118736","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T16:41:09Z","timestamp":1782492069000},"page":"118736","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["CDK4\/6-targeted therapy: From clinical inhibitors to emerging strategies to overcome resistance"],"prefix":"10.1016","volume":"141","author":[{"given":"Wenjie","family":"Sha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dijing","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zitong","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuo","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.bmc.2026.118736_bb0005","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.3390\/cells10123327","article-title":"Regulation of cell cycle progression by growth factor-induced cell Signaling","volume":"10","author":"Wang","year":"2021","journal-title":"Cells"},{"issue":"7918","key":"10.1016\/j.bmc.2026.118736_bb0010","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/s41586-022-04798-8","article-title":"Core control principles of the eukaryotic cell cycle","volume":"607","author":"Basu","year":"2022","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.bmc.2026.118736_bb0015","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.ccell.2021.03.010","article-title":"Targeting cell-cycle machinery in cancer","volume":"39","author":"Suski","year":"2021","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.bmc.2026.118736_bb0020","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41580-021-00404-3","article-title":"Cell cycle control in cancer","volume":"23","author":"Matthews","year":"2022","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"2","key":"10.1016\/j.bmc.2026.118736_bb0025","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/nrc.2016.138","article-title":"Cell cycle proteins as promising targets in cancer therapy","volume":"17","author":"Sicinski","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.bmc.2026.118736_bb0030","article-title":"CDK4\/6 activity is required during G(2) arrest to prevent stress-induced endoreplication","volume":"384(6695):eadi2421","author":"McKenney","year":"2024","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.bmc.2026.118736_bb0035","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3390\/cells10020293","article-title":"Targeting aberrant FGFR Signaling to overcome CDK4\/6 inhibitor resistance in breast Cancer","volume":"10","author":"Sobhani","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.bmc.2026.118736_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2024.101103","article-title":"Mechanisms of sensitivity and resistance to CDK4\/CDK6 inhibitors in hormone receptor-positive breast cancer treatment","volume":"76","author":"Glaviano","year":"2024","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.bmc.2026.118736_bb0045","article-title":"CDK4 and CDK6 kinases: from basic science to cancer therapy","volume":"375(6577):eabc1495","author":"Fassl","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.bmc.2026.118736_bb0050","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.895729","article-title":"Prognostic and predictive value of CCND1\/cyclin D1 amplification in breast Cancer with a focus on postmenopausal patients: A systematic review and Meta-analysis","volume":"13","author":"Jeffreys","year":"2022","journal-title":"Front Endocrinol"},{"issue":"9","key":"10.1016\/j.bmc.2026.118736_bb0055","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1080\/13543776.2024.2379926","article-title":"A patent review of small molecule CDK4\/6 inhibitors in the treatment of cancer: 2020-present","volume":"34","author":"Huang","year":"2024","journal-title":"Expert Opin Ther Pat"},{"issue":"1","key":"10.1016\/j.bmc.2026.118736_bb0060","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1038\/s41598-024-53151-8","article-title":"Comparative overall survival of CDK4\/6 inhibitors in combination with endocrine therapy in advanced breast cancer","volume":"14","author":"Kappel","year":"2024","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.bmc.2026.118736_bb0065","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s43018-024-00893-z","article-title":"Resistance mechanisms and therapeutic strategies of CDK4 and CDK6 kinase targeting in cancer","volume":"6","author":"Asciolla","year":"2025","journal-title":"Nat Cancer"},{"issue":"6","key":"10.1016\/j.bmc.2026.118736_bb0070","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/S1470-2045(23)00172-9","volume":"24","author":"Zhang","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bmc.2026.118736_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2023.107455","article-title":"Myeloprotection with trilaciclib in Chinese patients with extensive-stage small cell lung cancer receiving chemotherapy: results from a randomized, double-blind, placebo-controlled phase III study (TRACES)","volume":"188","author":"Cheng","year":"2024","journal-title":"Lung Cancer"},{"issue":"2","key":"10.1016\/j.bmc.2026.118736_bb0080","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s40265-024-02144-y","article-title":"Efficacy and safety of CDK4\/6 inhibitors: A focus on HR+\/HER2- early breast Cancer","volume":"85","author":"Klocker","year":"2025","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/j.bmc.2026.118736_bb0085","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1158\/2159-8290.CD-20-1726","article-title":"INK4 tumor suppressor proteins mediate resistance to CDK4\/6 kinase inhibitors","volume":"12","author":"Li","year":"2022","journal-title":"Cancer Discov"},{"issue":"10","key":"10.1016\/j.bmc.2026.118736_bb0090","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.ccell.2021.08.007","article-title":"Restoring order at the cell cycle border: co-targeting CDK4\/6 and CDK2","volume":"39","author":"Jeselsohn","year":"2021","journal-title":"Cancer Cell"},{"issue":"7","key":"10.1016\/j.bmc.2026.118736_bb0095","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1158\/1535-7163.MCT-11-0963","article-title":"Cyclin E2 overexpression is associated with endocrine resistance but not insensitivity to CDK2 inhibition in human breast cancer cells","volume":"11","author":"Caldon","year":"2012","journal-title":"Mol Cancer Ther"},{"issue":"8","key":"10.1016\/j.bmc.2026.118736_bb0100","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1158\/0008-5472.CAN-15-0728","article-title":"Early adaptation and acquired resistance to CDK4\/6 inhibition in Estrogen receptor-positive breast Cancer","volume":"76","author":"Herrera-Abreu","year":"2016","journal-title":"Cancer Res"},{"issue":"16","key":"10.1016\/j.bmc.2026.118736_bb0105","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1038\/onc.2016.379","article-title":"Acquired CDK6 amplification promotes breast cancer resistance to CDK4\/6 inhibitors and loss of ER signaling and dependence","volume":"36","author":"Yang","year":"2017","journal-title":"Oncogene"},{"key":"10.1016\/j.bmc.2026.118736_bb0110","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/bs.apcsb.2022.11.009","article-title":"Insights into the aberrant CDK4\/6 signaling pathway as a therapeutic target in tumorigenesis","volume":"135","author":"Rezaeian","year":"2023","journal-title":"Adv Protein Chem Struct Biol"},{"issue":"16","key":"10.1016\/j.bmc.2026.118736_bb0115","first-page":"1066","article-title":"Dalpiciclib in combination with letrozole\/anastrozole or fulvestrant in HR-positive and HER2-negative advanced breast cancer: results from a phase Ib study","volume":"40","author":"Zhang","year":"2024","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.bmc.2026.118736_bb0120","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s13058-023-01701-9","article-title":"Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+\/HER2- advanced breast cancer receiving first-line ribociclib plus fulvestrant","volume":"25","author":"Neven","year":"2023","journal-title":"Breast Cancer Res"},{"issue":"2","key":"10.1016\/j.bmc.2026.118736_bb0125","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/s12276-025-01395-3","article-title":"Targeting CDK4\/6 in breast cancer","volume":"57","author":"Shanabag","year":"2025","journal-title":"Exp Mol Med"},{"issue":"11","key":"10.1016\/j.bmc.2026.118736_bb0130","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1158\/2159-8290.CD-18-0264","article-title":"The genetic landscape and clonal evolution of breast Cancer resistance to Palbociclib plus Fulvestrant in the PALOMA-3 trial","volume":"8","author":"O\u2019Leary","year":"2018","journal-title":"Cancer Discov"},{"issue":"6241","key":"10.1016\/j.bmc.2026.118736_bb0135","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1126\/science.aab1433","article-title":"DRUG DEVELOPMENT. Phthalimide conjugation as a strategy for in vivo target protein degradation","volume":"348","author":"Winter","year":"2015","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.bmc.2026.118736_bb0140","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.cell.2019.11.031","article-title":"Proteolysis-targeting chimeras as therapeutics and tools for biological discovery","volume":"181","author":"Burslem","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.bmc.2026.118736_bb0145","article-title":"Prediction of allosteric druggable pockets of cyclin-dependent kinases","volume":"23(4):bbac290","author":"Ning","year":"2022","journal-title":"Brief Bioinform"},{"issue":"2","key":"10.1016\/j.bmc.2026.118736_bb0150","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1002\/med.21856","article-title":"Analyzing the scaffold diversity of cyclin-dependent kinase inhibitors and revisiting the clinical and preclinical pipeline","volume":"42","author":"Bharate","year":"2022","journal-title":"Med Res Rev"},{"key":"10.1016\/j.bmc.2026.118736_bb0155","article-title":"Cyclin-dependent kinases as therapeutic targets in cancer: recent advances, challenges, and opportunities","volume":"70442","author":"Ju","year":"2026","journal-title":"Int J Cancer"},{"issue":"23","key":"10.1016\/j.bmc.2026.118736_bb0160","doi-asserted-by":"crossref","first-page":"18500","DOI":"10.1039\/C8NJ04306J","article-title":"Flavopiridol as cyclin dependent kinase (CDK) inhibitor: a review","volume":"42","author":"Deep","year":"2018","journal-title":"New J Chem"},{"key":"10.1016\/j.bmc.2026.118736_bb0165","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jbiotec.2015.02.032","article-title":"Discovery and development of Seliciclib. How systems biology approaches can lead to better drug performance","volume":"202","author":"Khalil","year":"2015","journal-title":"J Biotechnol"},{"issue":"8","key":"10.1016\/j.bmc.2026.118736_bb0170","first-page":"603","article-title":"An overview of CDK enzyme inhibitors in Cancer therapy. Current Cancer drug","volume":"23","author":"Peddaguravagari","year":"2023","journal-title":"Targets"},{"issue":"5","key":"10.1016\/j.bmc.2026.118736_bb0175","first-page":"1913","article-title":"CDK inhibitors in cancer therapy, an overview of recent development","volume":"11","author":"Zhang","year":"2021","journal-title":"Am J Cancer Res"},{"issue":"7","key":"10.1016\/j.bmc.2026.118736_bb0180","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1021\/jm049354h","article-title":"Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4\/6","volume":"48","author":"Toogood","year":"2005","journal-title":"J Med Chem"},{"issue":"2","key":"10.1016\/j.bmc.2026.118736_bb0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2021.188590","article-title":"Clinical considerations of CDK4\/6 inhibitors in triple-negative breast cancer","volume":"1876","author":"Wang","year":"2021","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"10","key":"10.1016\/j.bmc.2026.118736_bb0190","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1158\/1535-7163.MCT-16-0300","article-title":"Spectrum and degree of CDK drug interactions predicts clinical performance","volume":"15","author":"Chen","year":"2016","journal-title":"Mol Cancer Ther"},{"issue":"11","key":"10.1016\/j.bmc.2026.118736_bb0195","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1158\/1535-7163.1427.3.11","article-title":"Specific inhibition of cyclin-dependent kinase 4\/6 by PD 0332991 and associated antitumor activity in human tumor xenografts","volume":"3","author":"Fry","year":"2004","journal-title":"Mol Cancer Ther"},{"issue":"20","key":"10.1016\/j.bmc.2026.118736_bb0200","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","article-title":"Palbociclib and letrozole in advanced breast Cancer","volume":"375","author":"Finn","year":"2016","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.bmc.2026.118736_bb0205","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/bip.20868","article-title":"Structure-guided discovery of cyclin-dependent kinase inhibitors","volume":"89","author":"Fischmann","year":"2008","journal-title":"Biopolymers"},{"issue":"9","key":"10.1016\/j.bmc.2026.118736_bb0210","doi-asserted-by":"crossref","first-page":"6390","DOI":"10.1021\/acs.jmedchem.1c02064","article-title":"From structure modification to drug launch: A systematic review of the ongoing development of cyclin-dependent kinase inhibitors for multiple Cancer therapy","volume":"65","author":"Shi","year":"2022","journal-title":"J Med Chem"},{"issue":"10","key":"10.1016\/j.bmc.2026.118736_bb0215","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1093\/annonc\/mdz278","article-title":"Myelopreservation with the CDK4\/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib\/randomized phase II trial","volume":"30","author":"Weiss","year":"2019","journal-title":"Ann Oncol"},{"issue":"26","key":"10.1016\/j.bmc.2026.118736_bb0220","doi-asserted-by":"crossref","first-page":"42343","DOI":"10.18632\/oncotarget.16216","article-title":"Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4\/6 for use as an oral antineoplastic in patients with CDK4\/6 sensitive tumors","volume":"8","author":"Bisi","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.bmc.2026.118736_bb0225","article-title":"Transient CDK4\/6 inhibition protects hematopoietic stem cells from chemotherapy-induced exhaustion","volume":"9(387):eaal3986","author":"He","year":"2017","journal-title":"Sci Transl Med"},{"issue":"1","key":"10.1016\/j.bmc.2026.118736_bb0230","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s12967-017-1231-7","article-title":"CDK4\/6 inhibitor-SHR6390 exerts potent antitumor activity in esophageal squamous cell carcinoma by inhibiting phosphorylated Rb and inducing G1 cell cycle arrest","volume":"15","author":"Wang","year":"2017","journal-title":"J Transl Med"},{"key":"10.1016\/j.bmc.2026.118736_bb0235","first-page":"10","article-title":"CDK4\/6 inhibitors combined with fulvestrant for HR(+)\/HER2(\u2212) advanced breast cancer. Transl","volume":"3","author":"Zhang","year":"2022","journal-title":"Breast Cancer Res"},{"issue":"11","key":"10.1016\/j.bmc.2026.118736_bb0240","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1038\/s41591-021-01562-9","article-title":"Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial","volume":"27","author":"Xu","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.bmc.2026.118736_bb0245","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.693104","article-title":"Clinical and pharmacologic differences of CDK4\/6 inhibitors in breast Cancer","volume":"11","author":"George","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.bmc.2026.118736_bb0250","article-title":"Hepatic adverse events with CDK4\/6 inhibitors: a systematic review combining meta-analysis and FAERS database","volume":"1-11","author":"Tang","year":"2025","journal-title":"Expert Opin Drug Saf"},{"issue":"5","key":"10.1016\/j.bmc.2026.118736_bb0255","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1002\/cpt.1296","article-title":"Abemaciclib inhibits renal tubular secretion without changing glomerular filtration rate","volume":"105","author":"Chappell","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.bmc.2026.118736_bb0260","first-page":"152","article-title":"Trilaciclib: A first-in-class therapy to reduce chemotherapy-induced myelosuppression","volume":"18","author":"Young","year":"2022","journal-title":"Oncol Haematol"},{"issue":"1","key":"10.1016\/j.bmc.2026.118736_bb0265","doi-asserted-by":"crossref","first-page":"3350","DOI":"10.1038\/s41467-025-58647-z","article-title":"Bireociclib plus fulvestrant for HR+\/HER2- advanced female breast cancer progressed on or after endocrine therapy: phase 3 BRIGHT-2 study interim analysis","volume":"16","author":"Wang","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.bmc.2026.118736_bb0270","doi-asserted-by":"crossref","DOI":"10.1177\/17588359251353623","article-title":"Understanding and overcoming CDK4\/6 inhibitor resistance in HR+\/HER2- metastatic breast cancer: clinical and molecular perspectives","volume":"17","author":"da Silva","year":"2025","journal-title":"Ther Adv Med Oncol."},{"issue":"8","key":"10.1016\/j.bmc.2026.118736_bb0275","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1158\/2159-8290.CD-19-1390","article-title":"The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4\/6 inhibitors in patients with hormone receptor-positive metastatic breast Cancer","volume":"10","author":"Wander","year":"2020","journal-title":"Cancer Discov"},{"issue":"6","key":"10.1016\/j.bmc.2026.118736_bb0280","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.ccell.2018.11.006","article-title":"Loss of the FAT1 tumor suppressor promotes resistance to CDK4\/6 inhibitors via the hippo pathway","volume":"34","author":"Li","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bmc.2026.118736_bb0285","article-title":"AKT\/mTOR signaling modulates resistance to endocrine therapy and CDK4\/6 inhibition in metastatic breast cancers. NPJ precis","volume":"7(1):18","author":"Abu-Khalaf","year":"2023","journal-title":"Oncol"},{"key":"10.1016\/j.bmc.2026.118736_bb0290","article-title":"Drugging the PI3K\/AKT\/mTOR pathway in ER+ breast Cancer","volume":"24(5):4522","author":"Alves","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.bmc.2026.118736_bb0295","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1158\/1078-0432.CCR-19-0751","article-title":"Biomarker analyses of response to cyclin-dependent kinase 4\/6 inhibition and endocrine therapy in women with treatment-na\u00efve metastatic breast Cancer","volume":"26","author":"Finn","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.bmc.2026.118736_bb0300","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1038\/s41467-019-09068-2","article-title":"Aberrant FGFR signaling mediates resistance to CDK4\/6 inhibitors in ER+ breast cancer","volume":"10","author":"Formisano","year":"2019","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.bmc.2026.118736_bb0305","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1158\/2159-8290.CD-18-0830","article-title":"PTEN loss mediates clinical cross-resistance to CDK4\/6 and PI3K\u03b1 inhibitors in breast Cancer","volume":"10","author":"Costa","year":"2020","journal-title":"Cancer Discov"},{"issue":"8","key":"10.1016\/j.bmc.2026.118736_bb0310","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.3390\/cancers13081928","article-title":"Assessment of resistance mechanisms and clinical implications in patients with KRAS mutated-metastatic breast Cancer and resistance to CDK4\/6 inhibitors","volume":"13","author":"Raimondi","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bmc.2026.118736_bb0315","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2025.105860","article-title":"A translational journey into resistance: decoding the role of NF1 in CDK4\/6-inhibitor failure","volume":"118","author":"Schettini","year":"2025","journal-title":"EBioMedicine"},{"issue":"6","key":"10.1016\/j.bmc.2026.118736_bb0320","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1038\/s41588-025-02187-1","article-title":"APOBEC3 mutagenesis drives therapy resistance in breast cancer","volume":"57","author":"Gupta","year":"2025","journal-title":"Nat Genet"},{"issue":"1","key":"10.1016\/j.bmc.2026.118736_bb0325","doi-asserted-by":"crossref","first-page":"6607","DOI":"10.1038\/s41467-021-26935-z","article-title":"Abemaciclib is a potent inhibitor of DYRK1A and HIP kinases involved in transcriptional regulation","volume":"12","author":"Kaltheuner","year":"2021","journal-title":"Nat Commun"},{"issue":"33","key":"10.1016\/j.bmc.2026.118736_bb0330","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1038\/s41388-025-03468-z","article-title":"PTEN neddylation aggravates CDK4\/6 inhibitor resistance in breast cancer","volume":"44","author":"Liu","year":"2025","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.bmc.2026.118736_bb0335","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/s41698-025-01041-1","article-title":"IL-6 predicts CDK4\/6 inhibitor resistance, identifying STAT3 as a target in HR+\/HER2-negative metastatic breast cancer","volume":"9","author":"Kettner","year":"2025","journal-title":"NPJ Precis Oncol"},{"key":"10.1016\/j.bmc.2026.118736_bb0340","first-page":"14","article-title":"Identification of abemaciclib derivatives targeting cyclin-dependent kinase 4 and 6 using molecular dynamics, binding free energy calculation, synthesis, and pharmacological evaluation","author":"Zhou","year":"2023","journal-title":"Front Pharmacol"},{"issue":"7","key":"10.1016\/j.bmc.2026.118736_bb0345","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1111\/tbj.13703","article-title":"CDK4\/6 inhibitors plus endocrine therapy improve overall survival in advanced HR+\/HER2- breast cancer: A meta-analysis of randomized controlled trials","volume":"26","author":"Wang","year":"2020","journal-title":"Breast J"},{"issue":"6","key":"10.1016\/j.bmc.2026.118736_bb0350","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1053\/j.seminoncol.2024.01.002","article-title":"CDK4\/6 inhibitors in the treatment of metastatic breast cancer: focus on toxicity and safety","volume":"50","author":"Wekking","year":"2023","journal-title":"Semin Oncol"},{"key":"10.1016\/j.bmc.2026.118736_bb0355","doi-asserted-by":"crossref","DOI":"10.1177\/17588359241282499","article-title":"Advances in the mechanism of CDK4\/6 inhibitor resistance in HR+\/HER2- breast cancer","volume":"16","author":"Wu","year":"2024","journal-title":"Ther Adv Med Oncol"},{"issue":"4","key":"10.1016\/j.bmc.2026.118736_bb0360","first-page":"5","article-title":"Abstract P5-04-18: ARV-471, an oral estrogen receptor PROTAC degrader for breast cancer","volume":"79","author":"Flanagan","year":"2019","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.bmc.2026.118736_bb0365","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.ccr.2014.05.020","article-title":"CDK 4\/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors","volume":"26","author":"Vora","year":"2014","journal-title":"Cancer Cell"},{"issue":"20","key":"10.1016\/j.bmc.2026.118736_bb0370","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","article-title":"Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast Cancer","volume":"380","author":"Andr\u00e9","year":"2019","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.bmc.2026.118736_bb0375","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1056\/NEJMoa2214131","article-title":"Capivasertib in hormone receptor-positive advanced breast Cancer","volume":"388","author":"Turner","year":"2023","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.bmc.2026.118736_bb0380","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1093\/annonc\/mdu456","article-title":"Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2\u2020","volume":"25","author":"Piccart","year":"2014","journal-title":"Ann Oncol"},{"issue":"15","key":"10.1016\/j.bmc.2026.118736_bb0385","doi-asserted-by":"crossref","first-page":"4177","DOI":"10.1158\/1078-0432.CCR-20-2114","article-title":"Phase I\/II trial of exemestane, Ribociclib, and Everolimus in women with HR(+)\/HER2(\u2212) advanced breast Cancer after progression on CDK4\/6 inhibitors (TRINITI-1)","volume":"27","author":"Bardia","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bmc.2026.118736_bb0390","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1200\/PO.20.00280","article-title":"Genomic alterations in head and neck squamous cell carcinoma: level of evidence according to ESMO scale for clinical actionability of molecular targets (ESCAT)","volume":"5","author":"Marret","year":"2021","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.bmc.2026.118736_bb0395","article-title":"Phase II single-arm study of palbociclib and cetuximab in anti-EGFR na\u00efve patients with KRAS\/NRAS\/BRAF wild-type, metastatic colorectal cancer","volume":"30(10):oyaf305","author":"Sorah","year":"2025","journal-title":"Oncologist"},{"key":"10.1016\/j.bmc.2026.118736_bb0400","doi-asserted-by":"crossref","first-page":"S874","DOI":"10.1016\/j.annonc.2024.08.1451","article-title":"1396TiP Osimertinib combined with dalpiciclib in EGFR-mutant, CDK4\/6 pathway-altered, advanced NSCLC patients with acquired resistance to third-generation EGFR-TKIs: A phase II, prospective, multicenter, single-arm clinical trial","volume":"35","author":"Jiang","year":"2024","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.bmc.2026.118736_bb0405","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1038\/s41467-020-16170-3","article-title":"Acquired resistance to combined BET and CDK4\/6 inhibition in triple-negative breast cancer","volume":"11","author":"Ge","year":"2020","journal-title":"Nat Commun"},{"issue":"6","key":"10.1016\/j.bmc.2026.118736_bb0410","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/S1470-2045(19)30164-0","article-title":"Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Jiang","year":"2019","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.bmc.2026.118736_bb0415","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007126","article-title":"Efficacy, safety, and biomarker analysis of nivolumab in combination with abemaciclib plus endocrine therapy in patients with HR-positive HER2-negative metastatic breast cancer: a phase II study (WJOG11418B NEWFLAME trial)","volume":"11","author":"Masuda","year":"2023","journal-title":"J Immunother Cancer"},{"issue":"9","key":"10.1016\/j.bmc.2026.118736_bb0420","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1093\/jnci\/djac051","article-title":"Increased CD8+ T-cell infiltration and efficacy for multikinase inhibitors after PD-1 blockade in hepatocellular carcinoma","volume":"114","author":"Kikuchi","year":"2022","journal-title":"J Natl Cancer Inst"},{"issue":"10","key":"10.1016\/j.bmc.2026.118736_bb0425","doi-asserted-by":"crossref","first-page":"940","DOI":"10.15252\/msb.20167321","article-title":"De novo MYC addiction as an adaptive response of cancer cells to CDK4\/6 inhibition","volume":"13","author":"Tarrado-Castellarnau","year":"2017","journal-title":"Mol Syst Biol"},{"issue":"6282","key":"10.1016\/j.bmc.2026.118736_bb0430","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1126\/science.aac9935","article-title":"MYC regulates the antitumor immune response through CD47 and PD-L1","volume":"352","author":"Casey","year":"2016","journal-title":"Science"},{"issue":"7668","key":"10.1016\/j.bmc.2026.118736_bb0435","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/nature23465","article-title":"CDK4\/6 inhibition triggers anti-tumour immunity","volume":"548","author":"Goel","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.bmc.2026.118736_bb0440","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.661737","article-title":"Immunomodulatory effects of BRAF, MEK, and CDK4\/6 inhibitors: implications for combining targeted therapy and immune checkpoint blockade for the treatment of melanoma","volume":"12","author":"Lelliott","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.bmc.2026.118736_bb0445","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2025.107955","article-title":"Advances in cutaneous melanoma therapy: the emerging role of CDK4\/6 inhibitors","volume":"221","author":"Kim","year":"2025","journal-title":"Pharmacol Res"},{"issue":"5","key":"10.1016\/j.bmc.2026.118736_bb0450","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.21037\/tlcr-24-33","article-title":"CDK4\/6 inhibitor abemaciclib combined with low-dose radiotherapy enhances the anti-tumor immune response to PD-1 blockade by inflaming the tumor microenvironment in Rb-deficient small cell lung cancer","volume":"13","author":"Wang","year":"2024","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.bmc.2026.118736_bb0455","series-title":"Intermittent catheters","author":"Andrac","year":"2023"},{"key":"10.1016\/j.bmc.2026.118736_bb0460","series-title":"CDK Inhibitors","author":"Vakkalanka","year":"2022"},{"key":"10.1016\/j.bmc.2026.118736_bb0465","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.108080","article-title":"Discovery of a novel CDK4\/6 and HDAC dual-targeting agent for the treatment of hepatocellular carcinoma","volume":"154","author":"Niu","year":"2025","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.bmc.2026.118736_bb0470","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.118192","article-title":"Design and synthesis of novel cyclin-dependent kinase 4\/6(CDK4\/6) and histone deacetylase (HDAC) dual inhibitors: in vitro and in vivo anticancer activity","volume":"301","author":"Kim","year":"2026","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2026.118736_bb0475","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117495","article-title":"Discovery of dual CDK4\/6 and BRD4 inhibitor as apoptosis and autophagy inducers against NSCLC in vitro and in vivo","volume":"290","author":"Zhang","year":"2025","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2026.118736_bb0480","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117685","article-title":"Design, synthesis, and biological evaluation of novel CDK4\/6 and BRD4 dual inhibitors for treatment of KRAS-mutant NSCLC","volume":"292","author":"Tong","year":"2025","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2026.118736_bb0485","first-page":"4c01976","article-title":"Discovery of dual CDK6\/BRD4 inhibitor inducing apoptosis and increasing the sensitivity of ferroptosis in triple-negative breast Cancer","author":"Zhang","year":"2024","journal-title":"J Med Chem"},{"issue":"12","key":"10.1016\/j.bmc.2026.118736_bb0490","doi-asserted-by":"crossref","first-page":"13030","DOI":"10.1021\/acs.jmedchem.5c01058","article-title":"Design and synthesis of PARP\/CDK6 dual-target inhibitors modulating of Wnt\/\u03b2-catenin Signaling pathway for the treatment of BRCA wild-type TNBC","volume":"68","author":"Zhang","year":"2025","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2026.118736_bb0495","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106683","article-title":"Discovery of dual PARP and CDK6 inhibitors for triple-negative breast cancer with wild-type BRCA","volume":"139","author":"Wang","year":"2023","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.bmc.2026.118736_bb0500","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1693927","article-title":"Mechanistic optimization of inavolisib combined with CDK4\/6 inhibitors in the treatment of PIK3CA-mutated breast tumors","volume":"16","author":"Zhu","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.bmc.2026.118736_bb0505","first-page":"1","article-title":"Ying-Jie. Advancements in CDK-based dual-target inhibitors for Cancer therapy","volume":"32","author":"Bao-Kai","year":"2025","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.bmc.2026.118736_bb0510","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117465","article-title":"Combination therapy and dual-target inhibitors based on cyclin-dependent kinases (CDKs): emerging strategies for cancer therapy","volume":"289","author":"Hao","year":"2025","journal-title":"Eur J Med Chem"},{"issue":"2","key":"10.1016\/j.bmc.2026.118736_bb0515","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1158\/1535-7163.MCT-14-0388","article-title":"AMG 925 is a dual FLT3\/CDK4 inhibitor with the potential to overcome FLT3 inhibitor resistance in acute myeloid leukemia","volume":"14","author":"Li","year":"2015","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.bmc.2026.118736_bb0520","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.07.044","article-title":"Novel dual inhibitors targeting CDK4 and VEGFR2 synergistically suppressed cancer progression and angiogenesis","volume":"181","author":"Huang","year":"2019","journal-title":"Eur J Med Chem"},{"issue":"20","key":"10.1016\/j.bmc.2026.118736_bb0525","doi-asserted-by":"crossref","first-page":"15280","DOI":"10.1021\/acs.jmedchem.1c01311","article-title":"Indirubin derivatives as dual inhibitors targeting cyclin-dependent kinase and histone deacetylase for treating Cancer","volume":"64","author":"Cao","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2026.118736_bb0530","first-page":"10","article-title":"Management of adverse events during cyclin-dependent kinase 4\/6 (CDK4\/6) inhibitor-based treatment in breast cancer. Therapeutic advances","author":"Thill","year":"2018","journal-title":"Med Oncol"},{"issue":"11","key":"10.1016\/j.bmc.2026.118736_bb0535","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1001\/jamaoncol.2025.3687","article-title":"600- vs 400-mg first-line Ribociclib in hormone receptor\u2013positive\/ERBB2-negative advanced breast Cancer: the AMALEE randomized clinical trial","volume":"11","author":"Cardoso","year":"2025","journal-title":"JAMA Oncology"},{"issue":"14","key":"10.1016\/j.bmc.2026.118736_bb0540","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21145165","article-title":"Dual inhibition of CDK4\/6 and PI3K\/AKT\/mTOR Signaling impairs energy metabolism in MPM Cancer cells","volume":"21","author":"Bonelli","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"6","key":"10.1016\/j.bmc.2026.118736_bb0545","doi-asserted-by":"crossref","first-page":"587","DOI":"10.2174\/138161209787315594","article-title":"Designing multiple ligands \u2013 medicinal chemistry strategies and challenges","volume":"15","author":"Richard","year":"2009","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.bmc.2026.118736_bb0550","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106779","article-title":"Discovery and identification of a novel PI3K inhibitor with enhanced CDK2 inhibition for the treatment of triple negative breast cancer","volume":"140","author":"Yang","year":"2023","journal-title":"Bioorg Chem"},{"issue":"1","key":"10.1016\/j.bmc.2026.118736_bb0555","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s12943-021-01434-3","article-title":"Proteolysis-targeting chimeras (PROTACs) in cancer therapy","volume":"21","author":"Li","year":"2022","journal-title":"Mol Cancer"},{"issue":"1","key":"10.1016\/j.bmc.2026.118736_bb0560","doi-asserted-by":"crossref","first-page":"6509","DOI":"10.1038\/s41467-023-42233-2","article-title":"Expanding PROTACtable genome universe of E3 ligases","volume":"14","author":"Liu","year":"2023","journal-title":"Nat Commun"},{"issue":"3","key":"10.1016\/j.bmc.2026.118736_bb0565","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1021\/acs.jcim.1c01150","article-title":"Importance of three-body problems and protein-protein interactions in proteolysis-targeting chimera Modeling: insights from molecular dynamics simulations","volume":"62","author":"Li","year":"2022","journal-title":"J Chem Inf Model"},{"issue":"9","key":"10.1016\/j.bmc.2026.118736_bb0570","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.3390\/pharmaceutics17091160","article-title":"Recent advances in the development of pro-PROTAC for selective protein degradation","volume":"17","author":"Hakem","year":"2025","journal-title":"Pharmaceutics"},{"issue":"7","key":"10.1016\/j.bmc.2026.118736_bb0575","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s41568-025-00817-8","article-title":"Targeted protein degradation for cancer therapy","volume":"25","author":"Hinterndorfer","year":"2025","journal-title":"Nat Rev Cancer"},{"issue":"11","key":"10.1016\/j.bmc.2026.118736_bb0580","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/j.tips.2023.08.007","article-title":"Proteomic approaches advancing targeted protein degradation","volume":"44","author":"Sathe","year":"2023","journal-title":"Trends Pharmacol Sci"},{"issue":"18","key":"10.1016\/j.bmc.2026.118736_bb0585","doi-asserted-by":"crossref","first-page":"15996","DOI":"10.1021\/acs.jmedchem.4c01289","article-title":"The new frontier: merging molecular glue degrader and antibody-drug conjugate modalities to overcome strategic challenges","volume":"67","author":"Poudel","year":"2024","journal-title":"J Med Chem"},{"issue":"1","key":"10.1016\/j.bmc.2026.118736_bb0590","doi-asserted-by":"crossref","first-page":"2542357","DOI":"10.1080\/14756366.2025.2542357","article-title":"FDA-approved kinase inhibitors in PROTAC design, development and synthesis","volume":"40","author":"Kossakowski","year":"2025","journal-title":"J Enzyme Inhib Med Chem"},{"key":"10.1016\/j.bmc.2026.118736_bb0595","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116166","article-title":"Annual review of PROTAC degraders as anticancer agents in 2022","volume":"267","author":"Wang","year":"2024","journal-title":"Eur J Med Chem"},{"issue":"8","key":"10.1016\/j.bmc.2026.118736_bb0600","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1038\/s41416-023-02399-4","article-title":"PROTAC-mediated CDK degradation differentially impacts cancer cell cycles due to heterogeneity in kinase dependencies","volume":"129","author":"Kumarasamy","year":"2023","journal-title":"Br J Cancer"},{"issue":"6","key":"10.1016\/j.bmc.2026.118736_bb0605","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1053\/j.gastro.2024.01.025","article-title":"Dual inhibition of CDK4\/6 and XPO1 induces senescence with acquired vulnerability to CRBN-based PROTAC drugs","volume":"166","author":"Wang","year":"2024","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.bmc.2026.118736_bb0610","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/s41698-025-00931-8","article-title":"Targeting CDKs in cancer therapy: advances in PROTACs and molecular glues","volume":"9","author":"Marei","year":"2025","journal-title":"NPJ Precis Oncol."},{"issue":"16","key":"10.1016\/j.bmc.2026.118736_bb0615","doi-asserted-by":"crossref","first-page":"7575","DOI":"10.1021\/acs.jmedchem.9b00871","article-title":"Potent and preferential degradation of CDK6 via proteolysis targeting chimera degraders","volume":"62","author":"Su","year":"2019","journal-title":"J Med Chem"},{"issue":"19","key":"10.1016\/j.bmc.2026.118736_bb0620","doi-asserted-by":"crossref","first-page":"6321","DOI":"10.1002\/anie.201901336","article-title":"Development of dual and selective degraders of cyclin-dependent kinases 4 and 6","volume":"58","author":"Jiang","year":"2019","journal-title":"Angew Chem Int Ed Engl"},{"issue":"5","key":"10.1016\/j.bmc.2026.118736_bb0625","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/j.cell.2018.09.051","article-title":"Targeting CDK9 reactivates epigenetically silenced genes in Cancer","volume":"175","author":"Zhang","year":"2018","journal-title":"Cell"},{"issue":"13","key":"10.1016\/j.bmc.2026.118736_bb0630","doi-asserted-by":"crossref","first-page":"11354","DOI":"10.1021\/acs.jmedchem.4c00965","article-title":"Development of degraders of cyclin-dependent kinases 4 and 6 based on rational drug design","volume":"67","author":"He","year":"2024","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2026.118736_bb0635","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2025.118282","article-title":"10PL8 and 2fPL8 inhibit gastric cancer cell proliferation by targeting degradation of CDK6 proteins to arrest the cell cycle","volume":"128","author":"Zhang","year":"2025","journal-title":"Bioorg Med Chem"},{"issue":"4","key":"10.1016\/j.bmc.2026.118736_bb0640","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/s43018-021-00174-z","article-title":"Distinct CDK6 complexes determine tumor cell response to CDK4\/6 inhibitors and degraders","volume":"2","author":"Wu","year":"2021","journal-title":"Nat Cancer."},{"issue":"9","key":"10.1016\/j.bmc.2026.118736_bb0645","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2020.127106","article-title":"Selective CDK6 degradation mediated by cereblon, VHL, and novel IAP-recruiting PROTACs","volume":"30","author":"Anderson","year":"2020","journal-title":"Bioorg Med Chem Lett"},{"issue":"1","key":"10.1016\/j.bmc.2026.118736_bb0650","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1021\/acs.jmedchem.2c01648","article-title":"Targeted protein degradation induced by HEMTACs based on HSP90","volume":"66","author":"Li","year":"2023","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2026.118736_bb0655","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106637","article-title":"Development of PROTAC degrader probe of CDK4\/6 based on DCAF16","volume":"138","author":"Pu","year":"2023","journal-title":"Bioorg Chem"},{"issue":"19","key":"10.1016\/j.bmc.2026.118736_bb0660","doi-asserted-by":"crossref","first-page":"20464","DOI":"10.1021\/acs.jmedchem.5c01640","article-title":"Translational research on the Oral delivery of the cytotoxic PROTAC molecule via tumor-targeting prodrug strategy for triple-negative breast Cancer treatment","volume":"68","author":"Hu","year":"2025","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2026.118736_bb0665","article-title":"Systematic review of molecular biomarkers predictive of resistance to CDK4\/6 inhibition in metastatic breast Cancer","volume":"6","author":"Asghar","year":"2022","journal-title":"JCO Precis Oncol."},{"key":"10.1016\/j.bmc.2026.118736_bb0670","article-title":"Breakthroughs in treatment for hematological malignancies: latest updates on molecular glue, PROTACs and RNA degraders from ASH 2024","volume":"18(1):26","author":"Li","year":"2025","journal-title":"J Hematol Oncol"},{"issue":"20","key":"10.1016\/j.bmc.2026.118736_bb0675","doi-asserted-by":"crossref","first-page":"18247","DOI":"10.1021\/acs.jmedchem.4c01596","article-title":"Discovery of ZLC491 as a potent, selective, and orally bioavailable CDK12\/13 PROTAC degrader","volume":"67","author":"Zhou","year":"2024","journal-title":"J Med Chem"},{"issue":"16","key":"10.1016\/j.bmc.2026.118736_bb0680","doi-asserted-by":"crossref","first-page":"11066","DOI":"10.1021\/acs.jmedchem.2c00384","article-title":"Discovery of a highly potent and selective dual PROTAC degrader of CDK12 and CDK13","volume":"65","author":"Yang","year":"2022","journal-title":"J Med Chem"},{"issue":"1","key":"10.1016\/j.bmc.2026.118736_bb0685","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/s41392-024-01983-1","article-title":"Sequential responsive nano-PROTACs for precise intracellular delivery and enhanced degradation efficacy in colorectal cancer therapy","volume":"9","author":"Yang","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.bmc.2026.118736_bb0690","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112903","article-title":"First orally bioavailable prodrug of proteolysis targeting chimera (PROTAC) degrades cyclin-dependent kinases 2\/4\/6 in vivo","volume":"209","author":"Wei","year":"2021","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2026.118736_bb0695","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2025.102956","article-title":"Drug-drug interactions and special considerations in breast cancer patients treated with CDK4\/6 inhibitors: A comprehensive review","volume":"137","author":"Sahin","year":"2025","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"10.1016\/j.bmc.2026.118736_bb0700","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/s43856-024-00505-y","article-title":"Tissue distribution and retention drives efficacy of rapidly clearing VHL-based PROTACs","volume":"4","author":"Zhang","year":"2024","journal-title":"Commun Med"},{"issue":"1","key":"10.1016\/j.bmc.2026.118736_bb0705","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/s41467-024-44698-1","article-title":"Selective CK1\u03b1 degraders exert antiproliferative activity against a broad range of human cancer cell lines","volume":"15","author":"Nishiguchi","year":"2024","journal-title":"Nat Commun"},{"issue":"11","key":"10.1016\/j.bmc.2026.118736_bb0710","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1158\/0008-5472.CAN-21-2428","article-title":"Functional genomic analysis of CDK4 and CDK6 gene dependency across human Cancer cell lines","volume":"82","author":"Zhang","year":"2022","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.bmc.2026.118736_bb0715","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/s41568-022-00456-3","article-title":"Targeting CDK4 and CDK6 in cancer","volume":"22","author":"Goel","year":"2022","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"10.1016\/j.bmc.2026.118736_bb0720","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1158\/0008-5472.CAN-20-2121","article-title":"Differential regulation of Cancer progression by CDK4\/6 plays a central role in DNA replication and repair pathways","volume":"81","author":"Dai","year":"2021","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.bmc.2026.118736_bb0725","doi-asserted-by":"crossref","first-page":"4212","DOI":"10.1038\/s41467-023-39854-y","article-title":"The RNA-binding protein LRPPRC promotes resistance to CDK4\/6 inhibition in lung cancer","volume":"14","author":"Zhou","year":"2023","journal-title":"Nat Commun"},{"issue":"25","key":"10.1016\/j.bmc.2026.118736_bb0730","doi-asserted-by":"crossref","first-page":"21549","DOI":"10.1021\/jacs.5c01420","article-title":"Identification of actionable targeted protein degradation effector sites through site-specific ligand incorporation-induced proximity (SLIP)","volume":"147","author":"Xiao","year":"2025","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.bmc.2026.118736_bb0735","article-title":"Clinical utility of CDK4\/6 inhibitors in sarcoma: successes and future challenges","volume":"6","author":"Hsu","year":"2022","journal-title":"JCO Precis Oncol."},{"issue":"11","key":"10.1016\/j.bmc.2026.118736_bb0740","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/j.bmcl.2019.03.035","article-title":"Selective degradation of CDK6 by a palbociclib based PROTAC","volume":"29","author":"Rana","year":"2019","journal-title":"Bioorg Med Chem Lett"},{"issue":"2","key":"10.1016\/j.bmc.2026.118736_bb0745","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.chembiol.2018.11.006","article-title":"Homolog-selective degradation as a strategy to probe the function of CDK6 in AML","volume":"26","author":"Brand","year":"2019","journal-title":"Cell Chem Biol"},{"issue":"49","key":"10.1016\/j.bmc.2026.118736_bb0750","doi-asserted-by":"crossref","first-page":"22622","DOI":"10.1021\/jacs.2c09255","article-title":"Bridged proteolysis targeting chimera (PROTAC) enables degradation of undruggable targets","volume":"144","author":"Xiong","year":"2022","journal-title":"J Am Chem Soc"},{"issue":"10","key":"10.1016\/j.bmc.2026.118736_bb0755","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.3324\/haematol.2020.256313","article-title":"Inducible deletion of CDK4 and CDK6 - deciphering CDK4\/6 inhibitor effects in the hematopoietic system","volume":"106","author":"Maurer","year":"2021","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.bmc.2026.118736_bb0760","doi-asserted-by":"crossref","first-page":"6699","DOI":"10.1038\/s41467-023-42360-w","article-title":"Broad-spectrum kinome profiling identifies CDK6 upregulation as a driver of lenvatinib resistance in hepatocellular carcinoma","volume":"14","author":"Leung","year":"2023","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.bmc.2026.118736_bb0765","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41523-024-00617-7","article-title":"CDK4\/6i-treated HR+\/HER2- breast cancer tumors show higher ESR1 mutation prevalence and more altered genomic landscape","volume":"10","author":"Chaudhary","year":"2024","journal-title":"NPJ Breast Cancer."},{"issue":"23","key":"10.1016\/j.bmc.2026.118736_bb0770","doi-asserted-by":"crossref","first-page":"5096","DOI":"10.1158\/1078-0432.CCR-25-1406","article-title":"BET Bromodomain Inhibition Reverses CDK4\/6 Inhibitor Resistance in Estrogen Receptor\u2013Positive Breast Cancer via Induction of miR-34a-5p","volume":"31","author":"Liu","year":"2025","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.bmc.2026.118736_bb0775","doi-asserted-by":"crossref","first-page":"5597","DOI":"10.1038\/s41467-024-49875-w","article-title":"O-GlcNAcylation of MITF regulates its activity and CDK4\/6 inhibitor resistance in breast cancer","volume":"15","author":"Zhang","year":"2024","journal-title":"Nat Commun"},{"issue":"7856","key":"10.1016\/j.bmc.2026.118736_bb0780","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1038\/s41586-021-03474-7","article-title":"The AMBRA1 E3 ligase adaptor regulates the stability of cyclin D","volume":"592","author":"Chaikovsky","year":"2021","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.bmc.2026.118736_bb0785","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1021\/acscentsci.2c01317","article-title":"Rational chemical Design of Molecular Glue Degraders","volume":"9","author":"Toriki","year":"2023","journal-title":"ACS Cent Sci"},{"key":"10.1016\/j.bmc.2026.118736_bb0790","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2022.215808","article-title":"Developing PROteolysis TArgeting chimeras (PROTACs) for hematologic malignancies","volume":"544","author":"Wu","year":"2022","journal-title":"Cancer Lett"},{"issue":"1","key":"10.1016\/j.bmc.2026.118736_bb0795","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1038\/s41467-022-29081-2","article-title":"p16(INK4A)-deficiency predicts response to combined HER2 and CDK4\/6 inhibition in HER2+ breast cancer brain metastases","volume":"13","author":"Ni","year":"2022","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.bmc.2026.118736_bb0800","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/s41523-024-00699-3","article-title":"Predictors of response to CDK4\/6i retrial after prior CDK4\/6i failure in ER+ metastatic breast cancer","volume":"10","author":"Mai","year":"2024","journal-title":"NPJ Breast Cancer"},{"issue":"5","key":"10.1016\/j.bmc.2026.118736_bb0805","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1158\/0008-5472.CAN-20-2275","article-title":"Functional determinants of cell cycle plasticity and sensitivity to CDK4\/6 inhibition","volume":"81","author":"Kumarasamy","year":"2021","journal-title":"Cancer Res"},{"key":"10.1016\/j.bmc.2026.118736_bb0810","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116613","article-title":"Discovery of bivalent small molecule degraders of cyclin-dependent kinase 7 (CDK7)","volume":"276","author":"Ji","year":"2024","journal-title":"Eur J Med Chem"},{"issue":"4","key":"10.1016\/j.bmc.2026.118736_bb0815","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.chembiol.2025.03.001","article-title":"Targeted degradation of CDK9 potently disrupts the MYC-regulated network","volume":"32","author":"Toure","year":"2025","journal-title":"Cell Chem Biol."},{"issue":"2","key":"10.1016\/j.bmc.2026.118736_bb0820","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.apsb.2019.08.001","article-title":"Degradation of proteins by PROTACs and other strategies","volume":"10","author":"Wang","year":"2020","journal-title":"Acta Pharm Sin B"},{"issue":"2","key":"10.1016\/j.bmc.2026.118736_bb0825","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/s41401-020-0416-4","article-title":"Intrinsic and acquired resistance to CDK4\/6 inhibitors and potential overcoming strategies","volume":"42","author":"Xu","year":"2021","journal-title":"Acta Pharmacol Sin"},{"issue":"1","key":"10.1016\/j.bmc.2026.118736_bb0830","doi-asserted-by":"crossref","first-page":"5258","DOI":"10.1038\/s41467-022-32828-6","article-title":"High p16 expression and heterozygous RB1 loss are biomarkers for CDK4\/6 inhibitor resistance in ER(+) breast cancer","volume":"13","author":"Palafox","year":"2022","journal-title":"Nat Commun"},{"issue":"3","key":"10.1016\/j.bmc.2026.118736_bb0835","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/s41416-024-02750-3","article-title":"CDK4\/6 inhibitors dephosphorylate RNF26 to stabilize TSC1 and increase the sensitivity of ccRCC to mTOR inhibitors","volume":"131","author":"Liu","year":"2024","journal-title":"Br J Cancer"},{"issue":"21","key":"10.1016\/j.bmc.2026.118736_bb0840","doi-asserted-by":"crossref","first-page":"4543","DOI":"10.1158\/1078-0432.CCR-25-0950","article-title":"Human kallikrein 2: A novel lineage-specific surface target in prostate Cancer","volume":"31","author":"Shen","year":"2025","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.bmc.2026.118736_bb0845","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.108944","article-title":"Metabolic modulation by CDK4\/6 inhibitor promotes chemokine-mediated recruitment of T cells into mammary tumors","volume":"35","author":"Uzhachenko","year":"2021","journal-title":"Cell Rep"},{"issue":"18","key":"10.1016\/j.bmc.2026.118736_bb0850","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.1158\/0008-5472.CAN-21-3656","article-title":"CDK4\/6 inhibition enhances oncolytic virus efficacy by potentiating tumor-selective cell killing and T-cell activation in refractory glioblastoma","volume":"82","author":"Xiao","year":"2022","journal-title":"Cancer Res"},{"issue":"22","key":"10.1016\/j.bmc.2026.118736_bb0855","doi-asserted-by":"crossref","first-page":"15282","DOI":"10.1021\/acs.jmedchem.2c01218","article-title":"A versatile and sustainable multicomponent platform for the synthesis of protein degraders: proof-of-concept application to BRD4-degrading PROTACs","volume":"65","author":"Bhela","year":"2022","journal-title":"J Med Chem"},{"issue":"5","key":"10.1016\/j.bmc.2026.118736_bb0860","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1016\/j.apsb.2025.03.047","article-title":"First ATG101-recruiting small molecule degrader for selective CDK9 degradation via autophagy-lysosome pathway","volume":"15","author":"Zhong","year":"2025","journal-title":"Acta Pharm Sin B"},{"issue":"3","key":"10.1016\/j.bmc.2026.118736_bb0865","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202415323","article-title":"MicroRNA-triggered programmable DNA-encoded pre-PROTACs for cell-selective and controlled protein degradation","volume":"64","author":"Zhan","year":"2025","journal-title":"Angew Chem Int Ed"},{"key":"10.1016\/j.bmc.2026.118736_bb0870","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116901","article-title":"Recent advances in dual PROTACs degrader strategies for disease treatment","volume":"279","author":"Liu","year":"2024","journal-title":"Eur J Med Chem"},{"issue":"1","key":"10.1016\/j.bmc.2026.118736_bb0875","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1021\/acs.jmedchem.2c01791","article-title":"Degrader-antibody conjugates: emerging new modality","volume":"66","author":"Hong","year":"2023","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2026.118736_bb0880","article-title":"Abstract ND12: discovery of PF-07220060, a potent and selective CDK4 inhibitor","volume":"84(7_Suppl):ND12","author":"Anders","year":"2024","journal-title":"Cancer Res"},{"key":"10.1016\/j.bmc.2026.118736_bb0885","article-title":"Abstract P4-10-06: preclinical characterization of BGB-43395, a potential best-in-class CDK4 selective inhibitor with potent pharmacodynamic and anti-tumor activity in HR+HER2- breast cancer models","volume":"31(12_Suppl):P4-10-06","author":"Zhu","year":"2025","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bmc.2026.118736_bb0890","doi-asserted-by":"crossref","first-page":"1585574","DOI":"10.3389\/fonc.2025.1585574","article-title":"Integrating single-cell regulatory atlas and multi-omics data for differential treatment response and multimodal predictive modeling in CDK 4\/6 inhibitor-treated breast cancer","volume":"15","author":"Yan","year":"2025","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.bmc.2026.118736_bb0895","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1186\/s12967-025-06374-w","article-title":"Gene expression analysis in circulating tumour cells to determine resistance to CDK4\/6 inhibitors plus endocrine therapy in HR+\/HER2- metastatic breast cancer patients","volume":"23","author":"Gonz\u00e1lez-Conde","year":"2025","journal-title":"J Transl Med"},{"issue":"8","key":"10.1016\/j.bmc.2026.118736_bb0900","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105506","article-title":"Circulating tumor DNA mutational landscape and dynamics after progression on a CDK4\/6 inhibitor in the PACE phase II trial for metastatic HR-positive\/HER2-negative breast cancer","volume":"10","author":"Jeselsohn","year":"2025","journal-title":"ESMO Open"},{"issue":"1","key":"10.1016\/j.bmc.2026.118736_bb0905","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s12943-022-01535-7","article-title":"Clinical considerations for the design of PROTACs in cancer","volume":"21","author":"Nieto-Jim\u00e9nez","year":"2022","journal-title":"Mol Cancer"},{"key":"10.1016\/j.bmc.2026.118736_bb0910","article-title":"Strategies targeting tumor immune and stromal microenvironment and their clinical relevance","volume":"183","author":"Huang","year":"2022","journal-title":"Adv Drug Deliv Rev"}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089626001926?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089626001926?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T11:21:14Z","timestamp":1786015274000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089626001926"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":182,"alternative-id":["S0968089626001926"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2026.118736","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CDK4\/6-targeted therapy: From clinical inhibitors to emerging strategies to overcome resistance","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2026.118736","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118736"}}